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n Abstract: Leptin is an adipocyte-derived hormone involved in regulation of satiety, and it also appears to have a role in
breast cancer risk. Leptin therefore might be a useful indicator of the potential preventive effects of weight loss in breast cancer
survivors. In this study we examined whether the change in leptin levels could be predicted by weight loss in obese breast can-
cer survivors. The subjects in this study were participating in a randomized trial of an individualized approach towards weight
loss in Detroit, MI. Breast cancer survivors (body mass index of 30–44 kg ⁄ m2) were enrolled and fasting blood samples were
obtained for leptin analysis over 1 year of study. Leptin levels were available from at least two time points for 36 women, and
weight change ranged from a gain of 11% to a loss of 25% of baseline weight. Using a repeated-measures regression model,
both baseline leptin level and concurrent percent body fat were found to synergistically predict leptin levels. Thus, for women
with the same body fat, those with higher baseline leptin levels are predicted to exhibit smaller decreases in leptin with weight
loss. Similar results were obtained for body weight and body weight change, but the associations with body fat were stronger.
Breast cancer survivors with initially higher leptin levels may differ with regard to regulation of change in leptin during weight
loss resulting in relatively smaller changes in leptin with equivalent amounts of weight loss. n
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W eight gain leading to overweight and obesity isbecoming a world-wide epidemic that has
increased dramatically in prevalence during recent years
(1). This is a matter of great importance for the treat-
ment of breast cancer as recurrence rates and survival in
early-stage disease are both negatively impacted by
increased body weight in the vast majority of studies
that have been conducted (2–4). Unlike the effects of
obesity on de novo breast cancer risk, which is different
in pre- and postmenopausal women, the adverse effect
of increased body weight on recurrence risk and survi-
val has been evident in both pre- and postmenopausal
women (3,5). For example, in a large study of young
women, higher body mass was associated with tumors
of higher cellular proliferation and decreased survival
from breast cancer (6). Obesity also has been shown to
increase the risk of contralateral breast cancer (7).
Weight gain after treatment for breast cancer can
exacerbate pre-existing overweight. Women diagnosed
with breast cancer have been observed to gain weight,
which can negatively affect health status in survivorship
(8–11). In a Canadian study, weight gain after a diagno-
sis of breast cancer was greater in women treated with
chemotherapy (2.5 kg in the year after diagnosis) than
with surgery and ⁄ or hormonal therapy alone (0.6 kg)
(12). One small study showed that weight gain in breast
cancer patients was not greater than that in control
women; however, the breast cancer patients were
unique in that there was a significant increase in body
fat 6 months after chemotherapy (13). Other studies
also have shown that chemotherapy for breast cancer
results in sarcopenic weight gain, perhaps as a result of
decreased physical activity levels (10,14,15).
Several metabolic alterations associated with the
adverse health effects of increased body weight, and in
particular an increase in body fat, may affect breast
cancer recurrence risk. These include the effects of obes-
ity on insulin levels and oxidative stress (16–18). Eleva-
ted leptin levels also have been associated with
increased breast cancer risk and poor prognosis in
breast cancer (19,20), although not all studies agree
(21–24). Leptin is, however, associated with insulin
resistance, breast cancer cell proliferation, and possibly
anti-estrogen resistance (25–28). Leptin is an obesity-
related hormone secreted by adipose tissue, and it is
decreased following weight loss. The physiological role
of leptin may include signaling an increase in fat stores
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to suppress hunger (29). In obese persons, however, lep-
tin resistance develops. Leptin resistance has been sug-
gested to occur at levels higher than 25 ng ⁄ mL as
transport of leptin to the brain is saturated at those lev-
els (29). Thus, very high levels of leptin might not be
incrementally effective for curbing energy intake. This
brings into concern the observations made in most stud-
ies that breast cancer patients have significantly higher
blood leptin levels than women without cancer, but this
might not be the case in premenopausal women which
is consistent with observations that obesity protects
against premenopausal breast cancer risk (20,30–35).
We reported previously that the obese breast cancer sur-
vivors in our study had higher leptin levels than those
reported for breast cancer patients of mixed body
weight status (36). In breast cancer patients, regulation
of leptin pathways has not been investigated in as much
detail as it has in other obese persons.
A number of mechanisms by which leptin can
increase breast cancer risk are currently being exam-
ined. In vitro, leptin exerts proliferative effects in breast
cancer cells (37–39). Leptin also appears to be angio-
genic (19). In human breast tissues, leptin was detected
in the cancerous tissue, the surrounding normal tissue,
and in areas of atypical hyperplasia, but it was not
localized in the normal breast (37). Leptin has therefore
been hypothesized to be a reasonable target for inter-
ventions that aim to decrease breast cancer risk (40).
Leptin decreased more in obese breast cancer survivors
who lost 10% of their initial body weight versus those
losing less weight over 12 months (36). A decrease in
leptin levels, if disclosed to study subjects, might be a
motivating factor to lose weight because of its relation-
ship to breast cancer risk. Previous studies in obese
women, however, have indicated that high leptin levels
are associated with low resting energy expenditure
thereby affecting the extent of weight loss achieved
(41–43). It was therefore important to determine whe-
ther or not change in leptin levels can simply be predic-
ted by extent of weight or body fat loss in obese breast
cancer survivors or whether baseline leptin and body




Eligible subjects were aged 18–70. Study subjects
had stage I or II breast cancer diagnosed within the
past 4 years and were free of any recurrence as con-
firmed by a physician. Chemotherapy or radiation
therapy was to have been completed at least 3 months
previously with the exception of tamoxifen. Recruit-
ment sources included direct mail to Race for the Cure
participants, press releases and brochures at breast
clinics. The study was reviewed and approved by the
Institutional Review Board of Wayne State University.
Subjects gave informed, written consent to participate.
Details of the study have been published previously
(44), and in the present analysis 36 women who com-
pleted 12 months of study were included.
Forty-eight subjects were randomly assigned to one
of four groups: control, Weight Watchers (WW), indi-
vidualized counseling, or a combination of WW and
individualized counseling. Nine of the forty-eight
women did not complete 12 months of participation.
Subjects in the control arm received the National Can-
cer Institute’s ‘‘Action Guide to Healthy Eating’’ and
the ‘‘Food Guide Pyramid’’ pamphlets, but they
received no other dietary or exercise instructions or
help. For the WW arm, women were given free cou-
pons and encouraged to attend WW meetings but
received no other dietary or exercise instruction. For
the Individualized arm, women received telephone
counseling with a registered dietitian. Finally, for the
Combination arm, subjects received both individual-
ized counseling and were asked to attend weekly WW
meetings using free coupons. This resulted in a popu-
lation of women with varying amounts of weight loss
at 12 months.
Assessments
Women were asked to come to the appointments
after an overnight fast and to drink two glasses of
water in the morning. Plasma was prepared immedi-
ately after drawing blood at baseline, 3, 6 and
12 months and stored frozen at )70C until analysis.
Leptin levels were determined with commercial
enzyme immunoassays kits using a high-affinity poly-
clonal capture antibody (Linco Research, St. Charles,
MO). Levels of insulin were also measured by radio-
immunoassay (ICN Biomedicals Inc., Costa Mesa,
CA), and glucose levels were measured using a spec-
trophotometric assay with glucose oxidase (Sigma
Chemical Co., St. Louis, MO). Questionnaires were
administered at baseline and intervals thereafter to
capture demographic and health factors. At baseline,
3, 6, 9 and 12 months, the women were weighed in
clothing but without shoes using a Health-o-Meter
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Professional Beam Scale, model 402KLS (Bridgeview,
IL). Percent body fat was measured using tetrapolar
bioelectrical impedance (model BIA101S; RJL Sys-
tems, Clinton Township, MI). Height was measured
at baseline only.
Statistical Methods
The data were analyzed using SAS 9.1 software (SAS
Inc., Cary, NC). The data were normally distributed
and no transformation was needed prior to conducting
the analyses. Descriptive analyses were performed
using t-tests and other appropriate exploratory meas-
ures. For the main statistical analyses, we used repea-
ted-measures regression models with either leptin or
rate of change in leptin as the outcome measure. The
single within-subject factor used in the model was time.
Both body fat (or rate of change in body fat) and base-
line leptin levels were used as covariates in the model.
Tukey–Cramer adjustment was used for post-hoc pair-
wise comparison between the time-points. An unstruc-
tured within-subject correlation matrix was used for
the purpose of flexibility. These models were also con-
structed using body weight and weight change instead
of body fat and body fat change.
RESULTS AND DISCUSSION
Subjects and Baseline Leptin Levels
There were 36 subjects on whom at least two leptin
levels were available. Of the 48 women enrolled, six
dropped out before a second blood sample could be
obtained and another six did not have more than one
blood sample available due to difficulties with the
phlebotomy that are common in this population. For
the 36 subjects in this analysis, the mean age was
52 years (SD 9, range 36–69), BMI at baseline was
35 kg ⁄ m2 (SD 4, range 30–44), and only four of the
women were pre-menopausal. The majority of the 36
women were white; five were African-American and
one was native American. Of the 36 women, 11
gained weight over 12 months of the study and the
rest lost weight. Weight loss was a mean of 4.9% of
baseline weight at 12 months (SD 8.6%, range a gain
of 11.3% to a loss of 27.2%). Body fat was measured
by tetrapolar bioelectric impedance. This method may
underestimate body fat in obese persons relative to
dual energy x-ray absorptiometry, but it is sensitive
enough to detect changes in body fat (45). At baseline,
mean body fat was 39.4% (SD 2.9, n ¼ 36, range
47–34) and after 12 months it was 37.5% (SD 3.8,
n ¼ 36, range 44–25).
At baseline, leptin levels were available for 35
women as blood was not available from one woman at
baseline. The mean levels were 40.3 ng ⁄ mL (SD 17.5)
for 24 women taking tamoxifen and 33.6 ng ⁄ mL (SD
15.5) for 11 women not taking tamoxifen (p ¼ 0.286
from t-test for differences between the two groups),
and 38 ng ⁄ mL (SD 17) for all 35 women combined.
Other studies have also found higher levels of leptin in
breast cancer patients taking tamoxifen versus those
not taking tamoxifen (34,46). After 12 months on
study, mean leptin was 34 ng ⁄ mL (SD 19, n ¼ 31). As
a reference, American females in the National Health
and Nutrition Examination Survey (NHANES III) had
mean leptin levels of 26 and 35.4 ng ⁄ mL for women of
BMI 30–35 and over 35 kg ⁄ m2, respectively, and mean
leptin levels of 9.9 ng ⁄ mL for women in the normal
weight range (47).
Change in Leptin Levels
The pattern of change in leptin levels generally fol-
lowed the change in body fat and body weight. Leptin
levels in women classified by weight change category
are shown in Fig. 1. Leptin decreased in most of the 13
women who lost weight without any regain. A loss fol-
lowed by gain (regain in weight ranged 0.9–9 pounds)
occurred in 16 women during 12 months, and in these
women leptin levels generally mirrored the change in
weight. Seven women steadily increased weight from
baseline to 12 months. Leptin increased in four of these
seven women and leptin decreased in the remaining
three women, two of whom subsequently displayed a
weight loss at 18 months. Note that it is possible that
some women may have gained and lost weight in
between visits, or vice versa, which in turn could have
affected observed leptin levels. The data overall agree
with published studies indicating that leptin decreases
with decreases in body weight (48).
We then modeled unadjusted leptin levels as a func-
tion of the concurrent body fat values. This was a
3-point repeated-measures regression model, with
leptin values at 3, 6, and 12 months as the outcome.
Time was used as a within-subject factor in the model.
The covariates used in the model were the concurrent
body fat measurements at 3, 6, and 12 months, and
the baseline leptin measure for each subject. As indica-
ted in Table 1, concurrent body fat percentage (p ¼
0.002) and baseline leptin level (p ¼ 0.044) were both
positively associated with subsequent leptin levels.
182 • sen et al.
There was also a significant difference found across
measurements at different time points (p ¼ 0.006). As
is shown in Table 1 under ‘‘time effects’’, from month
3 onwards leptin levels followed an increasing trend.
A post hoc pairwise comparison with Tukey–Cramer
adjustment revealed that leptin levels at month 3 were
significantly lower than that at month 6 (p ¼ 0.008).
The other time changes were not significant (p > 0.1).
This indicates that there was a prominent drop in
mean leptin level between 0 and 3 months followed
by an overall increase in the later months. Controlling
the regression model either individually or collectively
for baseline tamoxifen use, insulin resistance (as fast-
ing glucose ⁄ insulin ratio), and waist-hip ratio did not
make any qualitative change in the findings.
We further explored how (if at all) change in body
fat would predict change in the leptin levels. We
formed the rate of change in leptin by subtracting the
baseline leptin measure from the 3, 6, and 12 month
measures and divided the raw change values by the
month of observation. This gave us a ‘‘rate of change’’
in leptin per month, and adjusted for unequal observa-
tion periods in comparing the change-scores. Using
this as the outcome variable, and baseline leptin level,
concurrent body fat change, and time (as a categorical
variable with three levels) as independent variables,
the analysis was carried out under a repeated-meas-
ures regression framework. The changes in body fat
values were constructed in a manner similar to the
leptin changes. Both baseline leptin level as well as
body fat change predicted change in leptin levels. The
results are shown in Table 1. The positive estimate
corresponding to the body fat variable indicated that
the change in leptin and change in body fat followed
a similar pattern (p < 0.0001). On the other hand, the
negative estimate corresponding to the baseline leptin
level signified that a higher starting level of leptin was
associated with a lower overall change in leptin values
(p ¼ 0.004). Thus, for persons with the same body
fat, those individuals with higher baseline leptin
would be predicted to decrease leptin levels to a smal-
ler extent.
The overall effect of the within-subject factor time
was also found to be significant (p ¼ 0.004). As
shown in Table 1, the negative regression coefficients
corresponding to the time effects indicated that rate of

















































100 Weight loss followed by gain
Figure 1. Change in body weight and plasma leptin levels with
time in breast cancer survivors who were taking tamoxifen (open
circles, dashed line) or not taking tamoxifen (solid circles, solid
line). Graphs shown are for subjects who lost weight without
regain, lost and regained weight or gained weight over 12 months
of the study.
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change in leptin levels slowed with time. Once again,
the indication was that there was a sharp decrease in
levels within the first 3 months into the trial followed
by a flattening effect after 6 months. The pairwise
comparison indicated both the 6 and 12 month rate of
changes to be significantly slower than the 3 month
rate of changes, while the 6 and 12 month rates not
differing appreciably from each other. This is consis-
tent with the slower rate of weight loss, and weight
regain in some subjects, observed from 6 to
12 months. Once again, controlling for baseline tam-
oxifen use, insulin resistance, and waist-hip ratio as
potential confounders did not change the findings.
Very similar results were obtained with positive
and significant estimates for the overall effects of body
weight (b ¼ 0.197, p ¼ 0.001) and body weight
change (b ¼ 0.595, p < 0.0001) on leptin levels. Again
there was a negative estimate for baseline leptin (esti-
mate )0.0363, p ¼ 0.0022) indicating that higher
baseline leptin levels were associated with less change
in leptin over time in persons with the same body
weight. The finding of smaller decreases in leptin in
persons with initially higher leptin levels did not
appear to be a result of a smaller weight loss in per-
sons with the initially high leptin levels. Persons with
higher leptin generally weighed more at baseline (Pear-
son correlation coefficient r ¼ 0.420) and lost more
weight (average weight loss at 12 months was 5.8%
and 1.9% of baseline weight for initial leptin levels of
>25 versus <25 ng ⁄ mL, respectively). When using
body weight instead of body fat in the models, the
overall effect of the within-subject factor time was
found to be of only borderline significance. As leptin
is secreted by adipocytes, it is not surprising that the
relationships with body fat were stronger than with
body weight.
There are several reasons why persons with relat-
ively high levels of leptin initially might exhibit smal-
ler decreases in leptin with weight loss. If indeed
leptin resistance occurs above about 25 ng ⁄ mL (29),
then regulation of leptin may differ in persons with
high levels. In addition, leptin levels have been shown
to be only partly explained by body fat (29). Limita-
tions of this study are that the sample size was mod-
est, and the number of variables examined therefore
had to be limited. In addition, body fat was only
measured by bioelectric impedance, which may under-
estimate body fat in obese persons (45). The results,
however, do indicate that the effects of weight or
body fat change on leptin levels are expected to differ
by baseline leptin level. If leptin affects breast cancer
risk, this brings into importance research into the
factors that contribute to high leptin levels in breast
cancer survivors.
CONCLUSIONS
Obese breast cancer survivors who had relatively
high leptin levels for a given level of body fat at base-
line exhibited smaller decreases in leptin after weight
loss. Further investigation into the factors that con-
tribute to high leptin levels is warranted given the
possible importance of leptin in breast cancer out-
comes.
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